Previous Sectors

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year Abicipar sustained vision gains in year two with quarterly injections compared to monthly ranibizumab  Reductions in central retinal thickness were lower in [...]

2023-04-05T09:54:14+01:00October 14th, 2019|All News, Company News, Previous Sectors|

Allergan & Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation

The acceptance and authorisation are for Abicipar pegol in patients with neovascular (wet) age-related macular degeneration Filing includes data from two Phase 3 trials which evaluated the safety and efficacy of Abicipar quarterly dosing regimen Approvals in the United States and Europe are anticipated in 2020 DUBLIN, IRELAND – [...]

2023-04-05T09:50:32+01:00September 9th, 2019|All News, Company News, Previous Sectors|

Molecular Partners’ strategic partner Allergan announces that EMA has validated the marketing authorisation application for abicipar

Zurich-Schlieren, Switzerland, August 06, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced that the European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) of its strategic partner Allergan for abicipar, a [...]

2023-04-05T10:32:29+01:00August 7th, 2019|All News, Company News, Previous Sectors|

Molecular Partners and Amgen announce strategic collaboration in immuno-oncology

Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB MultiSpecific DARPin® Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE® Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products ZURICH-SCHLIEREN, SWITZERLAND and THOUSAND OAKS, Calif.– (Dec. 19, 2018) – Molecular Partners AG (SIX: [...]

2023-05-08T09:28:08+01:00December 19th, 2018|All News, Company News, Previous Sectors|

Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250

Zurich-Schlieren, May 30, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the first patient was dosed in the phase 2 multiple myeloma study of its lead oncology asset MP0250. In the first phase 2 [...]

2023-04-03T16:19:13+01:00May 30th, 2017|All News, Company News, Previous Sectors|

Patrick Amstutz Appointed as Molecular Partners’ Chief Executive Officer

Zurich-Schlieren, May 12, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., cofounder of the company, as Chief Executive Officer and to nominate him [...]

2023-05-04T15:52:45+01:00May 12th, 2017|All News, Company News, Previous Sectors|

Molecular Partners reports changes in ownership

Long-term venture capital investors holding reduced to 28% of share capital. Private investors acquired shares from venture capitalist investors in secondary block trades. Zurich-Schlieren, April 6, 2017. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today reported changes [...]

2023-04-12T15:20:59+01:00April 6th, 2017|All News, Company News, Previous Sectors|

Symetis and Boston Scientific reach USD 435 million purchase agreement

Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions Symetis’ [...]

2023-04-12T14:19:22+01:00March 3rd, 2017|All News, Company News, Previous Sectors|

Quid named a Tech Pioneer by World Economic Forum

Tianjin, People’s Republic of China, 27 June 2016 – Quid, headquartered in San Francisco, was today awarded as one of the World Economic Forum’s Technology Pioneers, a selection of the world’s most innovative companies. Quid is software that searches, analyzes and visualizes the world’s collective intelligence to help answer [...]

2023-04-12T11:13:33+01:00June 27th, 2016|All News, Company News, Previous Sectors|

First patient enrolled in phase III study of abicipar – Molecular Partners receives USD 15 million milestone payment

Zurich‐Schlieren, July 07, 2015. Molecular Partners AG (ticker: MOLN) today announced that its partner Allergan has initiated phase III clinical trials with abicipar pegol (abicipar) for the treatment of wet age‐related macular degeneration (wet AMD). The event triggered a clinical milestone payment to Molecular Partners of USD 15 million. [...]

2023-05-08T08:59:34+01:00July 7th, 2015|All News, Company News, Previous Sectors|
Go to Top